Process / pipelinedisease-specific-quality-of-life

MelasQoL (Melasma Quality of Life Scale)

MelasQoL is a disease-specific, patient-administered quality-of-life measure designed to assess the psychosocial burden of melasma, a common chronic disorder of symmetric facial hyperpigmentation. Developed by Cestari and colleagues in 2006, it captures the unique emotional and social impacts of a predominantly cosmetic condition that disproportionately affects women of color. MelasQoL is essential in clinical trials and observational studies of melasma treatments to ensure that efficacy encompasses meaningful quality-of-life outcomes.

Open in MethodMindSoonVideoSoon

Read the full method

Members only

Sign in with a free account to read this section.

Sign in

Sources

  1. Cestari TF, Hexsel D, Brandt FS, et al. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL. Br J Dermatol. 2006;156(Suppl 3):13-20. DOI: 10.1111/j.1365-2133.2006.07587.x
  2. Pandya AG, Hynan LS, Bhore R, et al. Reliability and validity of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011;64(1):78-83. DOI: 10.1016/j.jaad.2010.04.025

Related methods

Referenced by

ScholarGateMelasQoL (Melasma Quality of Life Scale). Retrieved 2026-06-04 from https://scholargate.app/en/dermatology/melasqol